It would be of great interest to investigate whether CDK5 (de)acetylation is involved in SIRT1/2-mediated signaling in various neurodegenerative diseases characterized by aberrant CDK5 activation8, and to determine whether the modulation of acetylated CDK5 levels is a viable therapeutic target. The gene discussed is CDK5; the disease is neurodegenerative disease.